On March 17, 2026 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) reported three of the Company’s internally-developed investigational oncology therapies will be presented across four poster sessions at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 taking place April 17-22 in San Diego, California. These next-generation candidates include: zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC) for small cell lung cancer (SCLC); ZL-6201, a leucine-rich repeat-containing protein 15 (LRRC15) ADC for the treatment of sarcoma and epithelial tumors with LRRC15 expressing cancer-associated fibroblasts (CAFs); and, ZL-1222, a PD-1 and interleukin-12 (IL-12) signaling attenuated mutein agonist immunocytokine for cancer immunotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The breadth and profile of our global oncology pipeline, highlighted by zoci, ZL-6201, and ZL-1222, underscore our commitment to developing innovative therapies for cancers that remain difficult to treat with current standards of care," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. "Leveraging our integrated U.S.-China development model, we are advancing these programs with speed and quality, and the data we will present at AACR (Free AACR Whitepaper) reinforces our confidence in these compounds."

Zoci targets DLL3, a validated therapeutic target for SCLC that is overexpressed in many neuroendocrine tumors and is generally associated with poor clinical outcomes. Zoci is on track to become Zai Lab’s first global oncology launch, with plans for three registration-enabling studies across 2L+ SCLC, 1L SCLC, and extrapulmonary NECs by the end of 2026. Its potential best-in-class safety profile, coupled with compelling systemic and intracranial efficacy, supports its potential role as a new standard of care in previously treated ES-SCLC, as well as a backbone ADC in first line combination regimens, including those that reduce the burdens of chemotherapy. Studies with other combinations and lines of therapies are planned.

LRRC15 is a type I transmembrane protein and an appealing target for cancer therapy because it is overexpressed in various mesenchymal tumors, such as sarcoma, glioblastoma and melanoma, as well as in CAFs across many other tumor types. Zai Lab is evaluating ZL-6201 as a potential first-in-class LRRC15-targeting ADC for the treatment of multiple solid tumors.

Interleukin-12 treatments have shown potential therapeutic benefit across a range of cancer types; however, narrow therapeutic windows and toxicity concerns have limited the utility of this therapeutic class. Zai Lab is evaluating ZL-1222 as a potential next-generation PD-1 and attenuated IL-12 immunocytokine bispecific protein for cancer immunotherapy across multiple indications, potentially combining potent antitumor activity with improved systemic safety.

Details regarding the Zai Lab poster presentations at AACR (Free AACR Whitepaper) 2026 are as follows:

Title: Discovery of ZL-6201, a novel LRRC15-targeting antibody drug conjugate (ADC) for the treatment of sarcomas and epithelial solid tumors
Session Title: Antibodies, Antibody-Drug Conjugates, and Nucleic Acids
Date/Time: Monday, April 20, 2026, from 9:00 a.m. – 12:00 p.m. PT
Location: San Diego Convention Center, Poster Section 38
Poster Board Number: 7
Publish Abstract Number: 2399

Title: ZL-1222, a PD-1-targeted potency-reduced IL-12 immunocytokine, overcomes PD-1 resistance and enhances antitumor immunity with an accepted safety profile
Session Title: Monoclonal Antibodies and Antibody-Cytokine Platforms
Date/Time: Tuesday, April 21, 2026, from 9:00 a.m. – 12:00 p.m. PT
Location: San Diego Convention Center, Poster Section 9
Poster Board Number: 2
Publish Abstract Number: 4331

Title: Intracranial activity of ZL-1310, a DLL3-targeted ADC, in patients with previously treated extensive-stage small cell lung cancer and baseline brain metastasis: Analysis of a phase 1 trial
Session Title: Phase 1 Clinical Trials
Date/Time: Tuesday, April 21, 2026, from 9:00 a.m. – 12:00 p.m. PT
Location: San Diego Convention Center, Poster Section 50
Poster Board Number: 15
Publish Abstract Number: CT193

Title: Preliminary results from the phase 1b/2, open-label, multi-center study of ZL-1310, a DLL3-targeted ADC, in patients with neuroendocrine carcinomas and other selected solid tumors
Session Title: Phase 1 Clinical Trials
Date/Time: Tuesday, April 21, 2026, from 9:00 a.m. – 12:00 p.m. PT
Location: San Diego Convention Center, Poster Section 50
Poster Board Number: 11
Publish Abstract Number: CT189

(Press release, Zai Laboratory, MAR 17, 2026, View Source [SID1234663645])